Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jiang-Ping Wu is active.

Publication


Featured researches published by Jiang-Ping Wu.


Bioorganic & Medicinal Chemistry Letters | 2008

Pyrazinoindolone inhibitors of MAPKAP-K2

Daniel R. Goldberg; Younggi Choi; Derek Cogan; M. Corson; Rodney P. DeLeon; Amy Gao; L. Gruenbaum; Ming-Hong Hao; D. Joseph; Mohammed A. Kashem; Craig Andrew Miller; Neil Moss; Matthew R. Netherton; Chris Pargellis; Josephine Pelletier; Rosemarie Sellati; Donna Skow; Carol Torcellini; Y.-C. Tseng; Ji Wang; R. Wasti; Brian Werneburg; Jiang-Ping Wu; Zhaoming Xiong

Optimization of pyrazinoindolone inhibitors of MAPKAP-K2 (MK2) provides a reasonable balance of cellular potency and physicochemical properties. Mechanistic studies support the inhibition of MK2 which is responsible for the sub-micromolar cellular efficacy.


Bioorganic & Medicinal Chemistry Letters | 2009

The discovery of thienopyridine analogues as potent IκB kinase β inhibitors. Part II

Jiang-Ping Wu; Roman Wolfgang Fleck; Janice R. Brickwood; Alison Capolino; Katrina Mary Catron; Zhidong Chen; Charles L. Cywin; Jonathan Emeigh; Melissa Foerst; John David Ginn; Matt Hrapchak; Eugene R. Hickey; Ming-Hong Hao; Mohammed A. Kashem; Jun Li; Weimin Liu; Tina Marie Morwick; Richard M. Nelson; Daniel R. Marshall; Leslie Martin; Peter Allen Nemoto; Ian Potocki; Michel Liuzzi; Gregory W. Peet; Erika Scouten; David Stefany; Michael Robert Turner; Steve Weldon; Clare Zimmitti; Denise Spero

An SAR study that identified a series of thienopyridine-based potent IkappaB Kinase beta (IKKbeta) inhibitors is described. With focuses on the structural optimization at C4 and C6 of structure 1 (Fig. 1), the study reveals that small alkyl and certain aromatic groups are preferred at C4, whereas polar groups with proper orientation at C6 efficiently enhance compound potency. The most potent analogues inhibit IKKbeta with IC50s as low as 40 nM, suppress LPS-induced TNF-alpha production in vitro and in vivo, display good kinase selectivity profiles, and are active in a HeLa cell NF-kappaB reporter gene assay, demonstrating that they directly interfere with the NF-kappaB signaling pathway.


Bioorganic & Medicinal Chemistry Letters | 2016

N-Arylsulfonyl-α-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity

Asitha Abeywardane; Gary O. Caviness; Younggi Choi; Derek Cogan; Amy Gao; Daniel R. Goldberg; Alexander Heim-Riether; Debra Jeanfavre; Elliott S. Klein; Jennifer A. Kowalski; Wang Mao; Craig Andrew Miller; Neil Moss; Philip Dean Ramsden; Ernest L. Raymond; Donna Skow; Lana Smith-Keenan; Roger J. Snow; Frank Wu; Jiang-Ping Wu; Yang Yu

Compound 1 ((4-amino-3,5-dichlorophenyl)-1-(4-methylpiperidin-1-yl)-4-(2-nitroimidazol-1-yl)-1-oxobutane-2-sulfonamido) was discovered to be a 690nM antagonist of human CCR10 Ca2+ flux. Optimization delivered (2R)-4-(2-cyanopyrrol-1-yl)-S-(1H-indol-4-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutane-2-sulfonamido (eut-22) that is 300 fold more potent a CCR10 antagonist than 1 and eliminates potential toxicity, mutagenicity, and drug-drug-interaction liabilities often associated with nitroaryls and anilines. eut-22 is highly selective over other GPCRs, including a number of other chemokine receptors. Finally, eut-22 is efficacious in the murine DNFB model of contact hypersensitivity. The efficacy of this compound provides further evidence for the role of CCR10 in dermatological inflammatory conditions.


Archive | 2003

Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses

Charles L. Cywin; Zhidong Chen; Jonathan Emeigh; Roman Wolfgang Fleck; Ming Hong Hao; Eugene R. Hickey; Weimin Will Liu; Daniel R. Marshall; Tina Marie Morwick; Peter Allen Nemoto; Ronald John Sorcek; Sanxing Sun; Jiang-Ping Wu


Archive | 2000

Imidazoimidazoles and triazoles as anti-inflammatory agents

Jiang-Ping Wu; Terence A. Kelly; Rene Marc Lemieux; Daniel R. Goldberg; Jonathan Emeigh; Ronald John Sorcek


Journal of Medicinal Chemistry | 2004

Second-generation lymphocyte function-associated antigen-1 inhibitors: 1H-imidazo[1,2-α]imidazol-2-one derivatives

Jiang-Ping Wu; Jonathan Emeigh; Donghong A. Gao; Daniel R. Goldberg; Daniel Kuzmich; Clara K. Miao; Ian Potocki; Kevin Chungeng Qian; Ronald John Sorcek; Deborah D. Jeanfavre; Kei Kishimoto; Elizabeth Mainolfi; Gerald H. Nabozny; Charline Peng; Patricia L. Reilly; Robert Rothlein; Rosemarie Sellati; Joseph R. Woska; Shirlynn Chen; Jocelyn A. Gunn; Drane O'Brien; and Stephen H. Norris; Terence A. Kelly


Organic Letters | 2005

Alkylation of magnesium sulfinates: a direct transformation of functionalized aromatic/heteroaromatic halides into sulfones.

Jiang-Ping Wu; Jonathan Emeigh; Xi-Ping Su


Archive | 1999

Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease

Terence A. Kelly; Barbara J. Bormann; Leah Lynn Frye; Jiang-Ping Wu


Archive | 2000

1-phenylpydrrolidin-2-ones and -thiones and 1-(4-pyridyl)pydrrolidin-2-ones and -thiones which are useful in the treatment of inflammatory disease

Terence A. Kelly; Jiang-Ping Wu; Daniel Kuzmich; Yancey David Ward; Leah Lynn Frye


Archive | 2009

Alpha-substituted n-sulfonyl gylcine amides antagonists of ccr10, compositions containing the same and methods for using them

Derek Cogan; Alexander Heim-Riether; Wang Mao; Craig Andrew Miller; Philip Dean Ramsden; Lana Louise Smith Keenan; Roger J. Snow; Jiang-Ping Wu; Yu Yang

Collaboration


Dive into the Jiang-Ping Wu's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge